Cadila Healthcare Limited Letrozole Export Data — India (DGFT 2022–2026)

Name: Cadila Healthcare Limited Letrozole Export Records India — #8 Exporter, 11 Shipments, $420.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Letrozole

India Pharmaceutical Trade Intelligence

$32.1M252 Suppliers117 CountriesHS 30049049

ExportsIndia → THAILAND48.3%India → UNITED STATES12.1%

ImportsSWITZERLAND → India$30.9K BELGIUM → India$7.4K

#1 Supplier: CIPLA LIMITED

Cadila Healthcare Limited — Letrozole Exporter #8 | $420.2K Trade Value | TransData Nexus | TransData Nexus

Cadila Healthcare Limited — Letrozole Exporter Profile

Indian Pharmaceutical Exporter · #8 for Letrozole · $420.2K export value · DGFT Verified

Cadila Healthcare Limited is the #8 Indian exporter of Letrozole with $420.2K in export value and 11 verified shipments. Cadila Healthcare Limited holds a 1.3% market share in Letrozole exports across 7 countries. The company exports 41 pharmaceutical products worth $34.9M across 17 therapeutic categories.

Cadila Healthcare Limited — Letrozole Export Profile: Buyers & Destinations

Cadila Healthcare Limited Letrozole export treemap — buyers and destination countries | TransData Nexus

Where Does Cadila Healthcare Limited Export Letrozole?

Country	Value	Shipments	Share
SRI LANKA	$101.8K	3	40.5%
THAILAND	$100.0K	2	39.8%
FRANCE	$15.5K	1	6.2%
INDONESIA	$13.9K	1	5.6%
SPAIN	$13.6K

Who Are the Top Buyers of Letrozole from Cadila Healthcare Limited?

Buyer	Country	Value	Orders
HEMAS PHARMACEUTICALS PRIVATE LIMITED	SRI LANKA	$101.8K	3
PHARMALAND 1982 CO LIMITED	THAILAND	$100.0K	2
CENTRE SPCIALITS PHARMACEUTIQUES ZI	FRANCE	$15.5K	1
PT MEGA LIFESCIENCES INDONESIA GEDUNG COWELL TOWER LT	INDONESIA	$13.9K	1
LABORATORIOS COMBIX SLU EDIFICIO	SPAIN	$13.6K	1
ZYDUS NIKKHO FARMACEUTICA LIMITEDA	BRAZIL	$5.5K	1
ZYDUS HEALTHCARE PHILIPPINES INC	PHILIPPINES	$750	2

Cadila Healthcare Limited supplies Letrozole to 7 buyers globally. The largest buyer is HEMAS PHARMACEUTICALS PRIVATE LIMITED (SRI LANKA), followed by PHARMALAND 1982 CO LIMITED (THAILAND) and CENTRE SPCIALITS PHARMACEUTIQUES ZI (FRANCE). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Letrozole Formulations Does Cadila Healthcare Limited Export?

Product Description / Formulation	Value	Shipments
LETOV 2.5MG TABLETS LETROZOLE 2.5MG 3X10 T UNDER LUT NO.AD240323012473N DT.14.03.2023 VALID UP TO DT.31.03.2024	$101.8K	3
LETOV 2.5MG LETROZOLE 3 X 10 T	$100.0K	2
LETROZOLE TAB 2.5 MG 30S PAC ZYDUS FRANLETROZOLEOTHER DTLS AS PER DOCUMENT	$15.5K	1
WAMISTRA Tablets 3x10 Tablets LETROZOLETABLETS USP 2.5MG 5623X3X10T	$13.9K	1
LETROZOL 2.5 MG COMBIX TABLETS LETROZOLE [3X10 PER PACK]	$13.6K	1
SABINE TABLETS 2.5 MG 30'S SALE BRAZIL LETROZOLE - serial nos .56259 to 5627856279 to 56279	$5.5K	1
LETOV 2.5 TABLETS LETROZOLE 3X10	$488	1
LETOV 2.5 TABLETS 3X10T LETROZOLE3X10	$262	1

Cadila Healthcare Limited exports 8 distinct Letrozole formulations including tablets, capsules, syrups, and combination drugs. The top formulation is LETOV 2.5MG TABLETS LETROZOLE 2.5MG 3X10 T UNDER LUT NO.AD24 with 3 shipments worth $101.8K.

How Does Cadila Healthcare Limited Compare to Nearest Letrozole Exporters?

Exporters ranked immediately above and below #8 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
6	NAPROD LIFE SCIENCES PRIVATE LIMITED	$581.6K	12	2	$48.5K
7	NATCO PHARMA LIMITED	$512.8K	29	6	$17.7K
8	CADILA HEALTHCARE LIMITED ★	$420.2K	11	7	$38.2K
9	INTAS PHARMACEUTICALS LTD	$280.6K	19	7	$14.8K
10	KHANDELWAL LABORATORIES PRIVATE LIMITED	$176.8K	27	4	$6.5K

Cadila Healthcare Limited ranks #8 among 252 Indian Letrozole exporters. Average shipment value of $38.2K compared to the market average of $74.0K. The closest competitors by value are NAPROD LIFE SCIENCES PRIVATE LIMITED and NATCO PHARMA LIMITED.

Which Indian Ports Ship Letrozole Exports?

Port	Shipments	% Share
SAHAR AIR	404	19.1%
SAHAR AIR CARGO ACC (INBOM4)	393	18.6%
MUNDRA SEA (INMUN1)	109	5.2%
AHEMDABAD AIR ACC (INAMD4)	107	5.1%
MUNDRA SEA	102	4.8%
DELHI AIR CARGO ACC (INDEL4)	100	4.7%
Bombay Air	99	4.7%
HYDERABAD AIR	89	4.2%

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Letrozole Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Zydus. The escalating conflict in the Middle East has disrupted key maritime routes, particularly the Red Sea and Suez Canal, leading to longer transit times and increased freight costs. Major carriers have suspended or restricted transits, extending transit times by 10–20 days and raising freight rates by 40–50% on key India–Europe routes. (livemint.com) This situation poses significant challenges for time-sensitive pharmaceutical shipments, especially temperature-sensitive medicines. (economictimes.indiatimes.com)

Conversely, U.S.–China trade tensions have prompted the U.S. to impose tariffs on Chinese pharmaceutical imports, creating an opportunity for Indian exporters to fill the supply gap. However, the U.S. has also introduced tariffs on Indian imports, including a 25% "reciprocal" tariff, followed by an additional 25% penalty tied to India's continued imports of Russian oil, bringing the total duty to 50%. (en.wikipedia.org) While pharmaceuticals are currently exempt, the potential for future tariffs necessitates strategic planning.

In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial. The FMD mandates stringent serialization and traceability requirements to prevent counterfeit medicines from entering the supply chain. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

Maintaining compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. FDA, WHO, and EU Good Manufacturing Practice (GMP) guidelines set stringent quality benchmarks. Any lapses can lead to import alerts, product recalls, or facility shutdowns. For instance, in 2019, Zydus's Moraiya facility received an Official Action Indicated (OAI) classification from the U.S. FDA, indicating that regulatory and/or administrative actions were recommended. (moneycontrol.com) Such events underscore the importance of robust quality assurance systems.

The evolving regulatory landscape demands continuous investment in compliance infrastructure. The EU's Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act (DSCSA) require advanced serialization and traceability measures. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Letrozole shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Cadila Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 11 individual customs records matching Cadila Healthcare Limited exporting Letrozole, covering 8 formulations to 7 countries via 7 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 117+ countries, 508+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Letrozole

Letrozole

Cadila Healthcare Limited — Letrozole Exporter Profile

Cadila Healthcare Limited — Letrozole Export Profile: Buyers & Destinations

Where Does Cadila Healthcare Limited Export Letrozole?

Who Are the Top Buyers of Letrozole from Cadila Healthcare Limited?

What Is India's Total Letrozole Export Value and How Much Does Cadila Healthcare Limited Contribute?

What Is the Average Shipment Value for Cadila Healthcare Limited's Letrozole Exports?

How Does Cadila Healthcare Limited Compare to Other Indian Letrozole Exporters?

What Letrozole Formulations Does Cadila Healthcare Limited Export?

How Does Cadila Healthcare Limited Compare to Nearest Letrozole Exporters?

Which Indian Ports Ship Letrozole Exports?

What Other Advanced Oncology Products Does Cadila Healthcare Limited Export?

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Letrozole Exports

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

About Cadila Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Letrozole Export Data from Cadila Healthcare Limited

Letrozole Stats

Company Overview

Top Products by Cadila Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source